Gilead Sciences

CompanyUnited StatesFounded 1987

RORWikidata

Gilead Sciences develops 27 assets, the furthest approved (axicabtagene ciloleucel in diffuse large B-cell lymphoma). Mostly small molecule and antibody acting on pol, PDCD1 and CD19; based in the United States, founded in 1987.

27
Assets
Furthest stage
Approved
270
Trials
707
Signals

Pipeline

27
  • Atripla

    Combination antiretroviral therapy comprising tenofovir disoproxil fumarate, emtricitabine, and efavirenz.

    Approved, discontinued in the US and EU, Small molecule, HIV infection, human immunodeficiency virus 1 infection

  • axicabtagene ciloleucel

    Engineered CAR T cells recognize CD19 and kill CD19-expressing B cells, including malignant cells.

    Approved, Cell therapy, CD19, diffuse large B-cell lymphoma, DLBCL Arising From Follicular Lymphoma

  • bictegravir

    HIV-1 integrase strand transfer inhibitor blocking viral DNA integration into host genome

    Approved, Small molecule, pol, HIV-1 infection (Phase 3)

24 more assets

Full company profiles: pipeline, trials, funding and people.

See Pro

Subsidiaries

1
  • Kite

    2 assets, 29 trials

In the full profile

  • Evidence behind the mechanisms11
  • Trials482
  • Deals4
  • Signals20
  • Similar companies6

Papers

Intelligence